Innovation Pharmaceuticals Inc (IPIX)

[loanranger]

"there's a lot of PE capital out there looking for good risk/return."

There's little doubt about that. But as you said "Don't be misled by pumping".

A strategic clinical priority is not the same thing as a fait accomplis...it's just a fancy way of saying "here's what we'd like do".

“Near-term strategic clinical priorities remain: to work closely with the FDA and other regulatory authorities to align on the remaining development plan necessary for Brilacidin in Oral Mucositis; to analyze the Prurisol Phase 2b data in Psoriasis; and, as additional funding becomes available, to commence work on new product formulations—1) an oral pill for Kevetrin in Ovarian Cancer; 2) an oral pill for Brilacidin in IBD; and a topical application for Brilacidin in Atopic Dermatitis and Acne.”

The strategic clinical priority to analyze the Prurisol Phase 2b data in Psoriasis has been in place for many months and the recent 10-K said the following (I know it's boilerplate...but at this stage it is very real):
"The Company intends on financing its future development activities largely from a variety of sources, including the sale of equity securities and seeking relationships with partners to help fund future clinical trial costs. However, there is no assurance these plans will be realized and that any additional financing will be available to us on satisfactory terms and conditions, if at all."

So if as you say "there's a lot of PE capital out there looking for good risk/return" then someone needs to point them in this direction quickly. Your belief that the phrase "and, as additional funding becomes available" that appears in the statement that follows "to analyze the Prurisol Phase 2b data in Psoriasis" serves as some kind of evidence that funding already exists for that analysis seems pretty shaky to me given that there is no other evidence whatsoever to suggest it.